CA3247129A1 - SERPINE PEPTIDES AND THEIR METHODS OF USE - Google Patents
SERPINE PEPTIDES AND THEIR METHODS OF USEInfo
- Publication number
- CA3247129A1 CA3247129A1 CA3247129A CA3247129A CA3247129A1 CA 3247129 A1 CA3247129 A1 CA 3247129A1 CA 3247129 A CA3247129 A CA 3247129A CA 3247129 A CA3247129 A CA 3247129A CA 3247129 A1 CA3247129 A1 CA 3247129A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- peptide
- serpin
- disease
- serpin peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263266444P | 2022-01-05 | 2022-01-05 | |
| US63/266,444 | 2022-01-05 | ||
| PCT/US2022/082669 WO2023133078A2 (en) | 2022-01-05 | 2022-12-30 | Serpin peptides and methods of using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3247129A1 true CA3247129A1 (en) | 2023-07-13 |
Family
ID=87074167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3247129A Pending CA3247129A1 (en) | 2022-01-05 | 2022-12-30 | SERPINE PEPTIDES AND THEIR METHODS OF USE |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20250161419A1 (https=) |
| EP (1) | EP4460322A4 (https=) |
| JP (1) | JP2025503607A (https=) |
| CN (1) | CN118804758A (https=) |
| AU (1) | AU2022431253A1 (https=) |
| CA (1) | CA3247129A1 (https=) |
| IL (1) | IL314135A (https=) |
| WO (1) | WO2023133078A2 (https=) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017040287A1 (en) * | 2015-08-28 | 2017-03-09 | Serpin Pharma, Llc | Methods for treatment of diseases |
| WO2017123401A1 (en) * | 2016-01-13 | 2017-07-20 | Children's Hospital Medical Center | Compositions and methods for treating allergic inflammatory conditions |
| EP3773727A4 (en) * | 2018-04-09 | 2022-05-04 | Yale University | BIFUNCTIONAL SMALL MOLECULES TO TARGETING THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS |
| KR20220099963A (ko) * | 2019-10-10 | 2022-07-14 | 예일 유니버시티 | 세포 수용체를 통한 분자 분해제로서의 조작된 항체 |
| US20210162029A1 (en) * | 2019-11-04 | 2021-06-03 | Azitra Inc | Compositions and methods for treatment or prevention of skin diseases and disorders with lekti |
| EP4003391A4 (en) * | 2020-07-06 | 2023-02-22 | Serpin Pharma, LLC | PEPTIDES AND METHODS OF USE THEREOF |
| AU2022222778A1 (en) * | 2021-02-22 | 2023-08-31 | Yale University | Targeted bifunctional degraders and methods using same |
-
2022
- 2022-12-30 IL IL314135A patent/IL314135A/en unknown
- 2022-12-30 JP JP2024540848A patent/JP2025503607A/ja active Pending
- 2022-12-30 CA CA3247129A patent/CA3247129A1/en active Pending
- 2022-12-30 EP EP22919262.0A patent/EP4460322A4/en active Pending
- 2022-12-30 US US18/726,945 patent/US20250161419A1/en active Pending
- 2022-12-30 AU AU2022431253A patent/AU2022431253A1/en active Pending
- 2022-12-30 WO PCT/US2022/082669 patent/WO2023133078A2/en not_active Ceased
- 2022-12-30 CN CN202280092284.4A patent/CN118804758A/zh active Pending
-
2023
- 2023-07-13 US US18/148,942 patent/US20230406906A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230406906A1 (en) | 2023-12-21 |
| AU2022431253A1 (en) | 2024-07-25 |
| WO2023133078A2 (en) | 2023-07-13 |
| EP4460322A2 (en) | 2024-11-13 |
| US20250161419A1 (en) | 2025-05-22 |
| IL314135A (en) | 2024-09-01 |
| JP2025503607A (ja) | 2025-02-04 |
| CN118804758A (zh) | 2024-10-18 |
| EP4460322A4 (en) | 2026-02-25 |
| WO2023133078A3 (en) | 2023-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Xu et al. | Methamphetamine exposure triggers apoptosis and autophagy in neuronal cells by activating the C/EBPβ‐related signaling pathway | |
| Liu et al. | Oxymatrine attenuates bleomycin-induced pulmonary fibrosis in mice via the inhibition of inducible nitric oxide synthase expression and the TGF-β/Smad signaling pathway | |
| US20240261364A1 (en) | Peptides and methods of using the same | |
| Elsherbiny et al. | ABT-702, an adenosine kinase inhibitor, attenuates inflammation in diabetic retinopathy | |
| Wu et al. | Recombinant adiponectin peptide promotes neuronal survival after intracerebral haemorrhage by suppressing mitochondrial and ATF4‐CHOP apoptosis pathways in diabetic mice via Smad3 signalling inhibition | |
| Chen et al. | Carbon monoxide ameliorates acetaminophen‐induced liver injury by increasing hepatic HO‐1 and Parkin expression | |
| Li et al. | Kaempferitrin attenuates unilateral ureteral obstruction‐induced renal inflammation and fibrosis in mice by inhibiting NOX4‐mediated tubular ferroptosis | |
| Ji et al. | SS-31 inhibits mtDNA–cGAS–STING signaling to improve POCD by activating mitophagy in aged mice | |
| Chen et al. | Asiatic acid alleviates cisplatin-induced renal fibrosis in tumor-bearing mice by improving the TFEB-mediated autophagy-lysosome pathway | |
| Tamai et al. | Caveolae in mesangial cells and caveolin expression in mesangial proliferative glomerulonephritis | |
| Lin et al. | Peroxisome proliferator-activator receptor γ and psoriasis, molecular and cellular biochemistry | |
| Cai et al. | Apratyramide, a marine-derived peptidic stimulator of VEGF-A and other growth factors with potential application in wound healing | |
| Yang et al. | Effect of Acer tegmentosum bark on atopic dermatitis-like skin lesions in NC/Nga mice | |
| Xu et al. | The NLRP3 activation in infiltrating macrophages contributes to corneal fibrosis by inducing TGF-β1 expression in the corneal epithelium | |
| US20190216901A1 (en) | Acth prophylactic treatment of renal disorders | |
| Cao et al. | Intracellular and extracellular Cyclophilin a promote cardiac fibrosis through TGF-β signaling in response to angiotensin Ⅱ | |
| US20250161419A1 (en) | Serpin peptides and methods of using the same | |
| Campo et al. | High-molecular weight hyaluronan reduced renal PKC activation in genetically diabetic mice | |
| HK40118659A (zh) | Serpin肽及其使用方法 | |
| US20250353898A1 (en) | Serpin peptide derivatives and methods of using the same | |
| HK40121727A (zh) | Serpin肽衍生物及其使用方法 | |
| Lee et al. | Protective Effect of Delta-Like 1 Homolog against muscular atrophy in a mouse model | |
| Piao et al. | Hydroxysafflor yellow A attenuates allergic airway inflammation by suppressing the activity of nuclear factor-kappa B in ovalbumin-induced asthmatic mice | |
| Chen et al. | Etomidate protects against homocysteine-induced blood-brain barrier disruption via upregulation of Krüppel-like factor 2 | |
| KR102115557B1 (ko) | 폐 섬유증의 예방 또는 치료용 약학적 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240705 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241210 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241210 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20241210 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20241211 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS Effective date: 20241211 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241227 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241227 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241227 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED Effective date: 20250304 Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT - OTHER THAN 5.09.01/02/03 DETERMINED NOT COMPLIANT Effective date: 20250304 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250916 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250916 |